ArticleFrontiers in oncology2025
Grape seed proanthocyanidins improve lymphatic drainage and blood perfusion in secondary lymphedema models.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Secondary lymphedema (SLE) is a chronic and debilitating condition that frequently arises following cancer treatments, particularly in breast cancer patients. Despite its increasing global prevalence and impact on patients' quality of life, there remains no effective pharmacological treatment for SLE. Grape seed proanthocyanidin extract (GSPE), a compound known for treating venous insufficiency, is hypothesized to enhance lymphatic function and may offer therapeutic value for managing SLE. This study aimed to evaluate the efficacy of GSPE in a rat model of secondary lymphedema. Methods: Fifteen nine-week-old Sprague-Dawley rats (weighing 250-300 g) were used in this study. Tail lymphedema was surgically induced in 12 rats to model SLE, while 3 rats served as normal controls. The lymphedema-induced rats were randomly assigned to either a treatment group (n=6) or a control group (n=6). The treatment group received intraperitoneal injections of GSPE powder dissolved in saline, whereas the control group received saline alone. Tail volume was measured periodically to monitor edema progression. Lymphatic and blood flow were assessed using near-infrared fluorescence indocyanine green lymphangiography (NIRF-ICGL) and laser Doppler flowmetry imaging (LDFI), respectively. Histological analysis was conducted using hematoxylin and eosin (H&E) staining. Results: The treatment group demonstrated a significant reduction of edema in the tail compared to the control group. NIRF-ICGL revealed improved lymphatic drainage, while LDFI analysis indicated enhanced blood perfusion in GSPE-treated animals. Histopathological examination showed reduced extracellular matrix deposition and fewer lymphatic abnormalities in the treatment group, suggesting mitigation of tissue fibrosis and lymphatic dysfunction. Discussion: These findings highlight the therapeutic potential of GSPE in treating secondary lymphedema. The observed improvements in lymphatic drainage, tissue perfusion, and histological features suggest that GSPE may exert beneficial effects beyond its established role in venous insufficiency. Considering the current lack of effective pharmacologic therapies for SLE, GSPE represents a promising candidate for future clinical applications. Further studies are warranted to validate its efficacy and safety in human subjects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.